Related Experiment Video
Updated: Oct 8, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.6K
Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation
Justin Haloot1, Lucijana Krokar1, Auroa Badin1
1University of Texas Health San Antonio, San Antonio, TX.
Journal of Atrial Fibrillation
|December 24, 2021
Summary
Sodium glucose cotransporter 2 (SGLT2) inhibitors show reduced cardioversion and mortality risks in atrial fibrillation (AF) patients. However, SGLT2 inhibitors were linked to a higher risk of ischemic stroke in this population.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sodium glucose cotransporter 2 (SGLT2) inhibitors are known for cardiovascular benefits.
- Limited data exists on SGLT2 inhibitors' impact on atrial fibrillation (AF) clinical outcomes.
Purpose of the Study:
- To compare ischemic stroke, acute coronary syndrome (ACS), cardioversion, and all-cause mortality in AF patients using SGLT2 inhibitors versus propensity-matched controls.
Main Methods:
- Retrospective study using a global medical research network database.
- Identified AF patients and those on SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) for at least one month.
- Propensity matched 26,269 AF patients based on demographics, comorbidities, procedures, and medications.
Main Results:
- SGLT2 inhibitors associated with lower risk of cardioversion (HR 0.921) and all-cause mortality (HR 0.676).
- Increased risk observed for ischemic stroke (HR 1.081).
- No clear association found with acute coronary syndrome (ACS) events.
Conclusions:
- SGLT2 inhibitor use in AF patients correlates with reduced cardioversion and all-cause mortality.
- Kaplan-Meier analysis suggests a higher probability of survival with SGLT2 inhibitors in AF patients.
- Further research is needed to understand the increased ischemic stroke risk.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.9K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
307
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
307
01:23Dipeptidyl Peptidase 4 Inhibitors
280
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
971
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
971
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.1K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.3K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K